NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/11/2024
Voltar para busca
Dado oficial do USPTO
VELOXIS PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Snapshot rápido
ST13
US500000079103548Classe
5, 40, 41, 42, 44, 45
Pedido
79103548
Registro
4212076
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
68
Atualização mais recente
08/11/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 40, 41, 42, 44, 45
Data de depósito
07/07/2011
Data de registro
25/09/2012
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/09/2022
Última transação
21/03/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
Cary, NC, US
Examinador
EINSTEIN, MATTHEW
Unidade examinadora
M60
Descrição da marca
The mark consists of the wording "VELOXIS PHARMACEUTICALS" below two curved lines.
Titulares e representantes
Titulares
Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals A/S
Representantes
Julia Anne Matheson Potomac Law Group, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 41Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsimmunotherapeutic and immunosuppressive preparations for medical use for treatment of transplant patients; pharmaceutical preparations and drug delivery systemspharmaceutical modified release systemspharmaceutical controlled release systemscomprised of tabletsgranulespillssachetspowderscapsulessolutions or fluidsall of the above for use in the treatment of mental and physical disordersemergencies and traumasagingallergy and immunologyburnsdiseases of the heart and blood vesselsdental and gum diseasesskin diseasesnutritional and dietary diseasesdiseases of the endocrinological system and pancreatic diseasesdiabetesepidemical diseasesdiseases and afflictions of the gastroenterological systemdiseases of the bloodinfectious diseasesneurological diseasesnephrological diseasesdiseases in the obstetrical and gynecological fieldcancerophthalmological diseasesdiseases and afflictions affecting the bonesjointscartilage material and musclesdiseases and afflictions of the earnose and throatdiseases and afflictions in the psychiatric fieldpulmonological diseases and afflictionsrheumatismurological diseases and afflictions and generalized pain
Classe 40
Treatment of materialsmillinggrindingmixingcompressingmelting of pharmaceuticalmedicinalbiotechnical and bacteriological substancespreparationsformulations and solutionsfor use in the pharmaceutical and medical industries
Classe 41
Education and training servicesarranging and conducting of seminarsworkshopsconferenceslectures and congressesall in the medicalchemical and pharmaceutical fields
Classe 42
Scientific and technological servicesscientific researchanalysis and testing in the field of medical sciencepharmacologybiotechnology and bacteriological areas and providing consultation and information relating thereto; design of drug delivery systems for medical use; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries
Classe 44
Medical and pharmaceutical assistance and consultationmedical and pharmaceutical information servicesproviding medical and scientific research information in the field of pharmaceuticals
Classe 45
Consultancy services regarding intellectual property; licensing of intellectual property; medical and pharmaceutical assistance and consultationincluding medical and pharmaceutical information services
Publicações
Histórico de despachos e eventos da marca no USPTO.
68 publicações encontradas
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
21/07/2023
INPC
INVALIDATION PROCESSED
14/06/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
14/05/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/03/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/03/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/03/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/03/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/03/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
14/09/2022
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
14/09/2022
ES71
TEAS SECTION 71 RECEIVED
12/09/2022
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
25/09/2021
CHLD
CHANGE OF OWNER RECEIVED FROM IB
18/09/2021
RNWL
INTERNATIONAL REGISTRATION RENEWED
22/07/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
21/05/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/02/2020
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
11/10/2019
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
22/06/2019
INPC
INVALIDATION PROCESSED
22/06/2019
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
29/05/2019
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
29/09/2018
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
29/09/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
27/09/2018
ES75
TEAS SECTION 71 & 15 RECEIVED
24/09/2018
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
17/09/2018
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
03/08/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
18/01/2018
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
25/09/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/07/2016
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
26/06/2015
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/09/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/03/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/02/2013
FIMP
FINAL DISPOSITION PROCESSED
11/02/2013
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/12/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
25/09/2012
GPNX
NOTIFICATION PROCESSED BY IB
23/07/2012
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/07/2012
PUBO
PUBLISHED FOR OPPOSITION
10/07/2012
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/06/2012
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
20/06/2012
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/06/2012
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/06/2012
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/05/2012
XAEC
EXAMINER'S AMENDMENT ENTERED
31/05/2012
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
31/05/2012
GNEA
EXAMINERS AMENDMENT E-MAILED
31/05/2012
CNEA
EXAMINERS AMENDMENT -WRITTEN
31/05/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/05/2012
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/05/2012
ALIE
ASSIGNED TO LIE
22/05/2012
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/05/2012
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/05/2012
RFNT
REFUSAL PROCESSED BY IB
19/12/2011
RFNT
REFUSAL PROCESSED BY IB
27/11/2011
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/11/2011
RFRR
REFUSAL PROCESSED BY MPU
08/11/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/11/2011
CNRT
NON-FINAL ACTION WRITTEN
07/11/2011
RFRR
REFUSAL PROCESSED BY MPU
03/11/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/11/2011
CNRT
NON-FINAL ACTION WRITTEN
01/11/2011
MAFR
APPLICATION FILING RECEIPT MAILED
01/11/2011
DOCK
ASSIGNED TO EXAMINER
28/10/2011
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/10/2011
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
27/10/2011
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
27/10/2011
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VELOXIS PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.